Table 1.
Socio-demographic and clinical characteristics of patients under the study.
| Categorya | No. of patients (n = 53) | Drug susceptibility status | P | ||
|---|---|---|---|---|---|
| pre-XDR | XDR | ||||
| Age | 15–29 | 28 (52.8%) | 24 (45.3%) | 4 (7.5%) | 0.94 |
| 30–44 | 15 (28.3%) | 13 (24.5%) | 2 (3.8%) | ||
| >45 | 10 (18.9%) | 9 (17%) | 1 (1.9%) | ||
| Sex | Male | 27 (50.9%) | 24 (45.3%) | 3 (5.7%) | 0.645 |
| Female | 26 (49.1%) | 22 (41.5%) | 4 (7.5%) | ||
| Area | Urban | 33 (62.3%) | 31 (58.5%) | 2 (3.7%) | 0.048* |
| Rural | 20 (37.7%) | 15 (28.3%) | 5 (9.4%) | ||
| Treatment history | New case | 3 (5.7%) | 3 (5.7%) | 0 (0%) | NAb |
| Retreatment | 50 (94.4%) | 43 (81.1%) | 7 (13.2%) | ||
| Default | 22 (44%) | 17 (34%) | 5 (10%) | 0.28 | |
| Relapse (n = 50)a | 15 (30%) | 14 (28%) | 1 (2%) | ||
| Failure | 13 (26%) | 12 (24%) | 1 (2%) | ||
a
Data were available for 53 patients, otherwise indicated.
An asterisk indicates a difference statistically significant.
b
Non-applicable. Since there were no new XDR-TB cases (n = 0), the statistical test could not be performed.